ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1724

A Feasible and Efficient Approach to Implementing Rheumatoid Arthritis Disease Activity Measure in a Busy Rheumatology Clinic: A Quality Improvement Project

Ali H.Ali1, Amani Elghafri2, Mosaab Mohameden3, Mandeep Sidhu2 and Candice Reyes Yuvienco4, 1University of California San Francisco Fresno, Fresno, CA, 2University of California San Francisco Fresno, Fresno, 3University of Cincinnati, Cincinnati, OH, 4University of California San Francisco Fresno, Clovis, CA

Meeting: ACR Convergence 2020

Keywords: Disease Activity, quality of care, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes Poster IV: Lifespan of a Disease

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has witnessed a substantial change over last the 20 years, with disease remission becoming an achievable goal. Treat-to-target philosophy, which shows improvement in outcome, is the recommended approach to managing RA. This includes regular evaluation of the disease activity and adjusting patient’s therapy as necessary to achieve the target of remission or low disease activity. The American College of Rheumatology recommends five tools for the measurement of disease activity in RA. Patient Activity Score II (PAS II) is one of these validated tools that quantify disease activity using patient-reported outcomes (PROs). Using these tools consistently can help guide therapy plans to achieve treat-to-target approach. We aim to enhance the use of PAS II in a busy rheumatology clinic using animation video and infographics.

Methods: The project was conducted over a 10-month period and was divided into two months pre-intervention period and eight months intervention period. Pre-intervention data about the use of any disease activity measure scale for all RA patients who were seen in the rheumatology clinic were collected. The intervention included distributing infographics (figure 1) and an animation video (see the link below) that explains the project to our rheumatology clinic providers. These were sent through emails and provided on-site our rheumatology clinic providers. The clinic staff received a brief session about the workflow process. PAS II questionnaire (figure 2) was distributed to all RA patients who have confirmed RA diagnosis to complete at the time of check-in. MDCalc (A free medical mobile application) was used by providers to calculate the PAS II score and insert the results in the visit note. The intervention period data about the use of PAS II was collected and compared with the pre-intervention data.

Results: Pre-intervention data showed that 4% (1/24) of RA patients had a documented disease activity measure in their charts. Intervention period data showed that 106 RA patients were seen in our clinic and 76% (81/106) had a documented PAS II scale in their charts. Most of them were seropositive 88%. In terms of disease activity, 56% had moderate disease activity, 23% had high disease activity and 21% were in remission or had low disease activity. We noticed that 45% of our RA patients are on biologics and 92% of these patients have PAS II scale in their charts.

Conclusion: We achieved our goal of implementing and maintaining the use of PAS II in a busy rheumatology clinic efficiently through the usage of infographics, simple animation video, PAS II questionnaire paper form, free mobile application, and single educational sessions for rheumatology clinic staff. We believe that our project may be applicable to other busy clinics as it is efficient, cost-effective, and feasible. PROs measures such as PASII, when consistently and judiciously used, may also help facilitate the acquisition of  highly expensive biologic treatments that would have encountered extreme health insurance coverage hurdles. Furthermore, regular documentation of disease activity can help researchers who target RA treatments to collect and analyze data more efficiently and more uniformly.

Figure 1. Workflow infographic

Figure 2: PAS II questionnaire

Video link and Bar code


Disclosure: A. H.Ali, None; A. Elghafri, None; M. Mohameden, None; M. Sidhu, None; C. Reyes Yuvienco, None.

To cite this abstract in AMA style:

H.Ali A, Elghafri A, Mohameden M, Sidhu M, Reyes Yuvienco C. A Feasible and Efficient Approach to Implementing Rheumatoid Arthritis Disease Activity Measure in a Busy Rheumatology Clinic: A Quality Improvement Project [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/a-feasible-and-efficient-approach-to-implementing-rheumatoid-arthritis-disease-activity-measure-in-a-busy-rheumatology-clinic-a-quality-improvement-project/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-feasible-and-efficient-approach-to-implementing-rheumatoid-arthritis-disease-activity-measure-in-a-busy-rheumatology-clinic-a-quality-improvement-project/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology